$21.14
+
$0.32 (1.54%)
End-of-day quote: 05/14/2024
NasdaqGM:SLN
Silence Therapeutics Annual Report
| Year | Year | 2022 | 2021 | 2020 | |||
|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$17.50M | $12.42M | $5.48M | ||
| GM % | Gross Margin % |
|
37.83% | 39.94% | 31.34% | ||
| OM | Operating Margin |
|
-277.66% | 0.00% | 0.00% | ||
| EPS | Earnings Per Share |
|
$0.00 | $-0.95 | $-1.53 | $-1.74 | $-1.64 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | ||
| PR % | Payout Ratio % |
|
0 | 0 | 0 | ||
| Sha. | Shares |
|
35.94m | 89.78m | 83.31m | ||
| OCF | Operating Cash Flow |
|
$-45.46M | $6.81M | $-10.78M | ||
| FCF | Free Cash Flow |
|
$-45.60M | $1.08M | $-11.29M | ||
| FCFS | Free Cash Flow Per Share |
|
$-1.43 | $0.06 | $-0.14 |
